How Have FDA Approvals Changed the Landscape of Microbiome Therapeutics? (GI & Endoscopy News)

In the past 18 months, the FDA has approved two fecal microbiota products, Rebyota and Vowst, for treating recurrent Clostridioides difficile infections. These approvals represent significant advancements in microbiome therapeutics, offering more standardized and accessible treatment options compared to traditional fecal microbiota transplants (FMT). However, challenges remain with payor coverage, patient accessibility, and the ongoing use of non–FDA-approved FMT options, which some providers continue to support due to their broader microbial composition.